UPDATE - Canaccord Genuity Initiates Coverage on HomeAway (AWAY) with a Hold; Growth with Modest Leverage
Tweet
Share
E-mailGet Alerts AWAY Hot Sheet
Price: $20.06 +0.05%
Rating Summary:
12 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - Canaccord Genuity initiates coverage on HomeAway (Nasdaq: AWAY) with a Hold rating. PT $30.
Analyst, Michael Graham, said, "We believe HomeAway is an undisputed leader in its sector. We expect the company’s high-quality management team will deliver reliable operating performance with a model marked by high visibility, pockets of seasonal upside and slowly-materializing operating leverage. We believe the stock should be owned more aggressively during periods when Internet sector sentiment is more risk-averse."
"Competition could intensify from both public (TripAdvisor (Nasdaq: TRIP) via Flipkey) and private (Airbnb) players, and HomeAway may not invest heavily enough to maintain its current lead. Property managers may never fully embrace the platform, dampening long-term growth prospects."
To see more ratings on AWAY, Click Here
Analyst, Michael Graham, said, "We believe HomeAway is an undisputed leader in its sector. We expect the company’s high-quality management team will deliver reliable operating performance with a model marked by high visibility, pockets of seasonal upside and slowly-materializing operating leverage. We believe the stock should be owned more aggressively during periods when Internet sector sentiment is more risk-averse."
"Competition could intensify from both public (TripAdvisor (Nasdaq: TRIP) via Flipkey) and private (Airbnb) players, and HomeAway may not invest heavily enough to maintain its current lead. Property managers may never fully embrace the platform, dampening long-term growth prospects."
To see more ratings on AWAY, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- TD Cowen Assumes Crescent Biopharma Inc (CBIO) at Buy
- TD Cowen Assumes Maze Therapeutics (MAZE) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
